Nutriband Inc NTRB

$6.65 +0.60 (9.92%)

Valuation

Market cap
73,544,000
Revenue TTM
$2,040,000
Net income TTM
$-8,230,000
PE ratio
0.00
Forward PE
—
Profit margin
-403.43%
Debt to equity
0.01

Trading

Volume
45,100
Avg volume
78,030
Day's range
$5.70 – $6.82
Shares out
12,156,000
Stochastic %K
33%
Beta
1.92
Analysts
Strong Sell
Price target
$15.00

Price

Company profile

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in...

Show more

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Industry
Biotechnology
Sector
Healthcare
Phone
407 377 6695
Website
https://www.nutriband.com
Address
121 South Orange Avenue, Suite 1500, Orlando, United States

Latest news

Stocktwits

nutriband_com Oct 8, 8:17 PM
📢 $NTRB Update Nutriband Inc. (NASDAQ: NTRB) has filed a new non-provisional patent application with the USPTO to strengthen intellectual property protection for its AVERSA™ abuse-deterrent transdermal technology. 🛡️ The application covers improved aversive formulations and coating methods designed to enhance abuse deterrence. 📅 If granted, the patent could extend protection for AVERSA™-based products, including AVERSA™ Fentanyl, through 2046. 🌎 AVERSA™ technology is currently protected by patents issued in 46 countries. 🔗 Full announcement: https://www.nutriband.com/post/nutriband-files-new-patent-application-to-strengthen-intellectual-property-protection #NTRB #Nutriband #AVERSA #Biotech #PatentProtection
0 replies
birdmanCap Oct 5, 8:14 PM
$NTRB Dude that Nick Shirley Doc was really eye opening ! More people need to see what this company is doing! 🇺🇸
0 replies
KlausSchwab Oct 5, 6:41 PM
$NTRB very unique company helping solve the very real fentanyl crisis in US
0 replies
nutriband_com Oct 3, 12:41 PM
📢 $NTRB Nutriband marks five years on Nasdaq. CEO Gareth Sheridan reflects on key milestones since the Company’s 2021 uplisting and outlines priorities ahead as AVERSA™ Fentanyl advances toward an IND filing and clinical development. The 2021 NTRBW warrants expired as scheduled on Sept. 30, 2026, with no extension or repricing. 🔗 Full CEO Letter: https://www.nutriband.com/post/nutriband-marks-five-years-on-nasdaq-ceo-letter-to-shareholders #NTRB #Nutriband #Nasdaq #AVERSA #Biotech
0 replies
birdmanCap Sep 30, 5:14 PM
$NTRB buy the dip
1 replies
RolandRickPerry Sep 29, 7:23 PM
$NTRB Report number IV. Deep dive on wildly optimistic price targets. No next week, a couple years from now. https://internetstockreview.com/report-iv-a-deeper-dive-into-nutribands-ntrb-price-targets/
1 replies
birdmanCap Sep 29, 6:32 PM
$NTRB holding well here
0 replies
nutriband_com Sep 29, 3:52 PM
📢 $NTRB Nutriband CEO Gareth Sheridan is featured in a new documentary by independent journalist Nick Shirley examining America’s opioid crisis. Sheridan discusses how Nutriband’s AVERSA™ technology is designed to help reduce abuse, misuse, diversion and accidental exposure associated with high-risk medications. ▶️ Full announcement & documentary: https://www.nutriband.com/post/nutriband-ceo-gareth-sheridan-featured-in-new-nick-shirley-documentary-confronting-america-s-opioid #NTRB #Nutriband #AVERSA #OpioidCrisis #DrugSafety
0 replies